Reporting Guidelines:
- Within 24 hours to local health department
Protocol:
- West Virginia IDEP Protocol
Current Case Definition:
- CDC Case Definition
Required Forms:
- WVEDSS
- WVEDSS Invasive Bacterial Disease – Neisseria meningitidis Case Report
General Information:
- Provider Information
- Public Information
- WV Office of Laboratory Services Transport Guidelines for Fastidious Organisms
- MCV4 Vaccine failure and AST Letter
Surveillance Data:
- West Virginia Meningococcal Disease, Invasive surveillance data from 1997-2006
- Meningococcal Disease, Invasive, by Age Group 1995-2005
- Meningococcal Disease, Invasive, by Month of Onset 1995-2005
- Meningococcal Disease, Invasive, by Year of Onset 1995-2005
- Meningococcal Disease, Invasive, by Serogroup and Year of Onset 2000-05
Other Links:
- National Foundation for Infectious Disease
- Guillain-Barre Syndrome Among Adolescents Who Received Meningococcal Conjugate Vaccine, Fact Sheet for Healthcare Professionals
- Guillain-Barre Syndrome Among Recipients of Menactra Meningococcal Congugate Vaccine – United States, June–July 2005
- FDA and CDC Issue Alert on Menactra Meningococcal Vaccine and Guillain Barré Syndrome
- CDC Information: Meningococcal Disease, Invasive
- Prevention and Control of Meningococcal Disease – Recommendations of the ACIP
- Prevention and Control of Meningococcal Disease and Meningococcal Disease and College Students – Recommendations of the ACIP
- Control and Prevention of Serogroup C Meningococcal Disease: Evaluation and Management of Suspected Outbreaks: Recommendations of the ACIP
- Laboratory-Based Surveillance for Meningococcal Disease in Selected Areas, United States, 1989-1991:
- Meningococcal Disease and College Students: Recommendations of the Advisory Committee on Immunization Practices
- CDC Guidelines for Vaccinating Pregnant Women
- Emergence of Fluoroquinolone-Resistant Neisseria meningitidis- Minnesota and North Dakota 2007-2008
- Recommendation from the ACIP for USe of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in Children Aged 2-10 years at Increased Risk for Invasive Menningococcal Disease